Drug intelligence / Profile preview

Undisclosed NASH molecule 2

Development stage: Preclinical
Lead developer: Mirscience Tx
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

Undisclosed NASH molecule 2 is a microRNA oligonucleotide therapeutic being developed by Mirscience Tx for the treatment of Non-Alcoholic Steatohepatitis (NASH), specifically targeting the fibrosis hallmark of the disease. Developed using the company's proprietary Mir-Discovery platform, the molecule is designed to modulate microRNA pathways that drive hepatic fibrosis. As of early 2024, the program is in the preclinical proof-of-concept stage and is part of a broader NASH portfolio that includes separate molecules for inflammation, lipid metabolism, and oxidative stress.

Other names: Mirscience Tx NASH molecule 2NASH molecule 2 (fibrosis)

Beyond the preview

Go deeper on Undisclosed NASH molecule 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Undisclosed NASH molecule 2.

Explore the full profile